- $64.37m
- -$50.66m
- $63.26m
Fortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview
Fortress Biotech Inc expected to post a loss of 49 cents a share - Earnings Preview
Fortress Biotech Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Fortress Biotech Reports 2024 Financial Results And Recent Corporate Highlights
Fortress Biotech Inc reports results for the quarter ended December 31 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 75 cents a share - Earnings Preview
Fortress Biotech Inc expected to post a loss of 75 cents a share - Earnings Preview
Checkpoint Therapeutics rises on $355 million Sun Pharma buyout deal
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million (updated)
Brief: Journey Medical Corporation Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi™ (Dfd-29) To Treat Rosacea
Brief: Fortress Biotech And Cyprium Therapeutics Announce U.S. FDA Acceptance And Priority Review Of NDA For CUTX-101
Brief: Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)
Fortress Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 59 cents a share - Earnings Preview
Fortress Biotech Inc expected to post a loss of 59 cents a share - Earnings Preview
FDA approves Journey Medical's drug for long-term skin condition
Brief: Highbridge Capital Management, Llc Reports 9% Passive Stake In Fortress Biotech, Inc. As Of Sept 30 - SEC Filing
Fortress Biotech Inc reports results for the quarter ended in June - Earnings Summary